Multiple-Dose Pharmacokinetic and Pharmacodynamic Interaction Between ABT-335, Rosuvastatin and Warfarin

NCT00487136 Phase 1 COMPLETED

This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in adult male subjects in general good health.

Details

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	COMPLETED
Enrolment	45
Start date	2007-06
Completion	2007-07

Conditions

• Healthy

Interventions

• Warfarin
• warfarin plus ABT-335 plus rosuvastatin 5 mg
• warfarin plus ABT-335 plus rosuvastatin 20 mg

Primary outcomes

• Pharmacokinetic parameters, pharmacodynamic variables — Day 24

Countries

United States